Play it again Sam
6 October 2008
Email
Share
M&A bankers may be in hibernation, but biotechs with saleable drugs are keeping big pharma up nights. Eli Lilly has offered a full price for Imclone, an asset with some strings attached. Rival suitor and natural partner BristolMyers Squibb isn t out of the running.